Al-Amri Ali M
Department of Internal Medicine/Oncology, College of Medicine, Imam Abdulrahman Bin Faisal University, King Fahd Hospital of the University, Al-Khobar, Eastern Province, Kingdom of Saudi Arabia.
Clin Lymphoma Myeloma Leuk. 2018 Mar;18(3):199-203. doi: 10.1016/j.clml.2018.01.002. Epub 2018 Jan 31.
Imatinib was the first tyrosine kinase inhibitor that has revolutionized the therapy of chronic myeloid leukemia. It binds breakpoint cluster region-Abelson kinase domain inducing apoptosis of the leukemic cells. In this study, we assessed the efficacy and toxicity of imatinib therapy in patients with chronic myeloid leukemia in chronic phase (CML-CP) in our hospital.
We retrospectively analyzed the outcome of 17 patients with CML-CP treated with imatinib.
The median age at the time of presentation was 35 years with male preponderance. The most common presenting clinical features were fatigue, abdominal distention, and discomfort. Forty-seven percent of patients had fever at presentation whereas 35.29% were referred to our hospital because of incidental findings of high blood cell counts. With a median follow-up of 8 years (range, 2-16 years) the overall survival is 100% and progression-free survival 85%. Two patients had acceptable adverse effects.
After a median follow-up of 8 years, imatinib was found to induce long survival with manageable side effect in adult Saudi patients with CML-CP.
伊马替尼是首个彻底改变慢性髓性白血病治疗方法的酪氨酸激酶抑制剂。它与断裂点簇集区-阿贝尔森激酶结构域结合，诱导白血病细胞凋亡。在本研究中，我们评估了伊马替尼治疗我院慢性期慢性髓性白血病（CML-CP）患者的疗效和毒性。
我们回顾性分析了17例接受伊马替尼治疗的CML-CP患者的治疗结果。
就诊时的中位年龄为35岁，男性居多。最常见的就诊临床特征为乏力、腹胀和不适。47%的患者就诊时发热，而35.29%的患者因偶然发现血细胞计数升高而转诊至我院。中位随访8年（范围2 - 16年），总生存率为100%，无进展生存率为85%。2例患者出现可耐受的不良反应。
中位随访8年后，发现伊马替尼可使成年沙特CML-CP患者长期生存，且副作用可控。
